Blog
RSS FeedPosted by Michael Wonder on 16 Jun 2022
Core network partners announced for CADTH’s post-market drug evaluation network
10 June 2022 - CADTH is pleased to announce the four successful core network partners of its inaugural post-market drug ...
Posted by Michael Wonder on 24 May 2022
HLS Therapeutics obtains public reimbursement for Vascepa in Quebec
24 May 2022 - Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with ...
Posted by Michael Wonder on 23 May 2022
Draft CADTH recommendation for Spinraza (nusinersen sodium) fails adults in need of treatment for spinal muscular atrophy
20 May 2022 - CADTH does not accept new evidence demonstrating Spinraza's effectiveness and safety for treating spinal muscular atrophy – ...
Posted by Michael Wonder on 17 May 2022
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults
17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...
Posted by Michael Wonder on 12 May 2022
CADTH expands scientific advice program to include advice on real world evidence
28 April 2022 - CADTH is expanding its scientific advice program to include applications for advice on real world evidence generation ...
Posted by Michael Wonder on 12 May 2022
After a 5 year fight to lower drug prices, Ottawa's pledge quietly falls apart
12 May 2022 - What began with a promise to protect Canadians ended with a commitment to support pharmaceutical companies. ...
Posted by Michael Wonder on 03 May 2022
Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases
3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...
Posted by Michael Wonder on 28 Apr 2022
Market for new medicines in Canada has not slowed over last two years, despite focus on COVID-19 treatments
28 April 2022 - An average of nine new medicines per quarter have been approved in Canada through the pandemic, ...
Posted by Michael Wonder on 28 Apr 2022
Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan
27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 26 Apr 2022
Amarin partner HLS Therapeutics completes reimbursement negotiations with Pan-Canadian Pharmaceutical Alliance for Vascepa (icosapent ethyl)
26 April 2022 - Amarin Corporation announced today its partner HLS Therapeutics has completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance for ...
Posted by Michael Wonder on 23 Apr 2022
Canada is settling for half measures on drug price regulations
22 April 2022 - After a two-year delay, new federal regulations for patented medicine prices will come into force this ...
Posted by Michael Wonder on 21 Apr 2022
Ontario family forced to fight for life-saving drug highlights need for national rare disease strategy
21 April 2022 - Beth Vanstone doesn’t want anyone else to have to fight for access to life saving medications. ...
Posted by Michael Wonder on 13 Apr 2022
Paxlovid ‘inaccessible’ to many patients in Canada. Here’s why that needs to change.
13 April 2022 - A pill to treat COVID-19 appears to be the country’s best hope, outside of vaccines and ...
Posted by Michael Wonder on 07 Apr 2022
CADTH launches consultations on proposals to enhance drug review processes
4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...
Posted by Michael Wonder on 05 Apr 2022
CADTH Strategy 2022-2025: anticipate, innovate and transform
5 April 2022 - CADTH is pleased to share Ahead of the Curve: Shaping Future-Ready Heath Systems, the agency's new ...